{"ok":true,"entry":{"slug":"umeclidinium","kind":"medication","name":"umeclidinium","aliases":["Incruse","Trelegy"],"brands_sg":["Incruse Ellipta","Anoro Ellipta","Trelegy Ellipta"],"class":"long-acting antimuscarinic bronchodilator","tags":["respiratory"],"use_for":"sg label: maintenance copd treatment, to relieve symptoms","use_after":"sg label: one inhalation once daily, same time each day","use_duration":null,"take_with":"inhaled · a short-acting reliever covers sudden symptoms","pros":["sg label: one inhalation once daily, nothing to swallow","sg label: no dose change for age or kidney problems","us label: no dose change in moderate liver problems"],"cons":["us label: not for relief of acute symptoms","us label: can worsen narrow-angle glaucoma","us label: can worsen urinary retention"],"dose_note":"every label read puts the ceiling at 62.5 micrograms of umeclidinium once daily; only the partners change. the singapore incruse ellipta label says 'The recommended dose is one inhalation of INCRUSE ELLIPTA once daily' and the us incruse label states the limit as 'Do not use INCRUSE ELLIPTA more than 1 time every 24 hours'. the us anoro ellipta label repeats it — 'Do not use ANORO ELLIPTA more than 1 time every 24 hours' — and the singapore trelegy label says 'The maximum recommended dosage is 1 inhalation of Trelegy Ellipta 200/62.5/25 mcg once daily', where the 62.5 mcg umeclidinium share is the same at either strength. extra doses are not a rescue treatment. the prescriber sets the product.","dosage":null,"ul_status":null,"sg_class":"prescription-only","cautions":["narrow-angle glaucoma (us label)","prostate enlargement or bladder-neck obstruction (us label)","severe milk-protein allergy — sg label: contraindicated","rapidly deteriorating copd — us label: not the setting to start it"],"clashes":[{"src":["fda_incruse_int"],"note":"us label: additive effects; co-administration is to be avoided","with":"other anticholinergic medicines"}],"sources":[{"id":"hsa_register","url":"https://data.gov.sg/datasets/d_767279312753558cbf19d48344577084/view","label":"HSA — Listing of Registered Therapeutic Products (data.gov.sg open dataset, 5,511 rows, cached in full and filtered locally)","quote":"All 4 umeclidinium rows read 'Prescription Only' — INCRUSE ELLIPTA 62.5 MCG/DOSE (umeclidinium alone, R03BB07) · ANORO ELLIPTA 62.5/25 (with vilanterol) · TRELEGY ELLIPTA 100/62.5/25 and 200/62.5/25 (with fluticasone furoate and vilanterol)","accessed":"2026-08-27"},{"id":"ndf_incruse","url":"https://www.ndf.gov.sg/about-drugs/product-information/SIN14853P","label":"National Drug Formulary (SG, MOH) — INCRUSE ELLIPTA INHALATION POWDER 62.5 MCG/DOSE [SIN14853P], indications, dosing and contraindications, last updated 28 Jul 2026","quote":"indicated for maintenance bronchodilator treatment to relieve symptoms associated with chronic obstructive pulmonary disease (COPD) … The recommended dose is one inhalation of INCRUSE ELLIPTA once daily … contraindicated in patients with severe milk-protein allergy","accessed":"2026-08-27"},{"id":"ndf_trelegy","url":"https://www.ndf.gov.sg/about-drugs/product-information/SIN15806P","label":"National Drug Formulary (SG, MOH) — TRELEGY ELLIPTA INHALATION POWDER 100/62.5/25 MCG [SIN15806P], Dosage and Administration","quote":"The maximum recommended dosage is 1 inhalation of Trelegy Ellipta 200/62.5/25 mcg once daily … Do not use Trelegy Ellipta more than 1 time every 24 hours.","accessed":"2026-08-27"},{"id":"fda_incruse_ind","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22INCRUSE+ELLIPTA%22&limit=1","label":"US FDA label — INCRUSE ELLIPTA (umeclidinium, GSK), section 1 Indications and Usage, via openFDA (effective 13 Dec 2023)","quote":"INCRUSE ELLIPTA is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).","accessed":"2026-08-27"},{"id":"fda_incruse_dose","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22INCRUSE+ELLIPTA%22&limit=1","label":"US FDA label — INCRUSE ELLIPTA, section 2 Dosage and Administration, via openFDA","quote":"INCRUSE ELLIPTA should be used at the same time every day. Do not use INCRUSE ELLIPTA more than 1 time every 24 hours … No dosage adjustment is required for geriatric patients, patients with renal impairment","accessed":"2026-08-27"},{"id":"fda_incruse_warn","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22INCRUSE+ELLIPTA%22&limit=1","label":"US FDA label — INCRUSE ELLIPTA, section 5 Warnings and Precautions, via openFDA","quote":"Do not initiate in acutely deteriorating COPD. Do not use to treat acute symptoms … Acute symptoms should be treated with an inhaled, short-acting beta2-agonist … Worsening of narrow-angle glaucoma may occur … Worsening of urinary retention may occur","accessed":"2026-08-27"},{"id":"fda_incruse_int","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22INCRUSE+ELLIPTA%22&limit=1","label":"US FDA label — INCRUSE ELLIPTA, section 7 Drug Interactions, via openFDA","quote":"Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of INCRUSE ELLIPTA with other anticholinergic-containing drugs.","accessed":"2026-08-27"},{"id":"fda_anoro_dose","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ANORO+ELLIPTA%22&limit=1","label":"US FDA label — ANORO ELLIPTA (umeclidinium and vilanterol, GSK), section 2 Dosage and Administration, via openFDA (effective 2 Jun 2023)","quote":"The recommended dosage of ANORO ELLIPTA for maintenance treatment of COPD is 62.5 mcg umeclidinium and 25 mcg vilanterol … once daily by oral inhalation … Do not use ANORO ELLIPTA more than 1 time every 24 hours.","accessed":"2026-08-27"}],"brand_certs":null,"updated_at":"2026-08-29T16:16:33.302383+08:00"},"disclaimer":"kozen-x is not a medical device and does not give medical advice. it lists what published sources have written down. absence of a record is not the same as safe."}